Phase IIIb Study for Relapsed/Refractory Pediatric/Young Adult Acute Lymphoblastic Leukemia Patients to be Treated With CTL019
Phase of Trial: Phase III
Latest Information Update: 20 Jan 2020
Price : $35 *
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 17 Jan 2020 This trial is completed in Spain, according to European Clinical Trials Database record.
- 24 Dec 2019 This trial has been completed in Austria, according to European Clinical Trials Database
- 15 Nov 2019 Planned number of patients changed from 72 to 80.